These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15714423)

  • 21. Combination therapy in the management of mixed dyslipidaemia.
    Cannon CP
    J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes.
    Zdravkovic V; Hamilton JK; Daneman D; Cummings EA
    J Pediatr; 2006 Dec; 149(6):845-849. PubMed ID: 17137905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
    Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
    Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
    Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
    Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
    Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
    Warshauer JT; Lopez X; Gordillo R; Hicks J; Holland WL; Anuwe E; Blankfard MB; Scherer PE; Lingvay I
    Diabetes Metab Res Rev; 2015 Oct; 31(7):734-44. PubMed ID: 25959529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
    Magkos F; Brennan A; Sweeney L; Kang ES; Doweiko J; Karchmer AW; Mantzoros CS
    Metabolism; 2011 Jul; 60(7):1045-9. PubMed ID: 21081243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actos (pioglitazone).
    TreatmentUpdate; 2001; 13(7):5-6. PubMed ID: 11794862
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pioglitazone].
    Yokoi H
    Nihon Rinsho; 2011 Sep; 69 Suppl 7():378-89. PubMed ID: 22519020
    [No Abstract]   [Full Text] [Related]  

  • 35. Complications & side effects. Disappointing result for rosiglitazone and lipodystrophy.
    TreatmentUpdate; 2004 Mar; 16(2):7. PubMed ID: 17219670
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current options of insulin resistence correction in patients with metabolic syndrome].
    Demidova TIu; Ametov AS; Titova OI
    Ter Arkh; 2006; 78(10):36-40. PubMed ID: 17180935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversing the tide of metabolic syndrome.
    Dumas MA
    Nurs Manage; 2003 Jun; 34 Suppl Guide():1-5. PubMed ID: 12867772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effects of "pioglitazone", an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1.
    Hafez VG; Bosseila M; Abdel Halim MR; Shaker OG; Kamal M; Kareem HS
    J Dermatolog Treat; 2015 Jun; 26(3):208-14. PubMed ID: 24902962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
    Calmy A; Hirschel B; Hans D; Karsegard VL; Meier CA
    AIDS; 2003 Mar; 17(5):770-2. PubMed ID: 12646807
    [No Abstract]   [Full Text] [Related]  

  • 40. Thiazolidinedione therapy for managing metabolic syndrome.
    Geurin MD; St Anna L
    Am Fam Physician; 2010 Dec; 82(12):1553-4. PubMed ID: 21166377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.